8-K
filed September 1, 2023, 7:59 PM ET
CIK 0001142596
M&A
confidence high
sentiment neutral
materiality 0.90
NUVASIVE INC: M&A transaction — NuVasive completes merger with Globus Medical, shareholders get 0.75 GMED shares
NUVASIVE INC
- Merger closed Sep 1, 2023; NuVasive shareholders received 0.75 Globus Medical Class A shares per NUVA share.
- NuVasive common stock to be delisted from Nasdaq after Form 25 filed; reporting obligations to be suspended.
- CEO J. Christopher Barry and CFO Matthew Harbaugh depart; Daniel Scavilla named CEO, Keith Pfeil CFO of NuVasive.
- All prior directors cease; Scavilla and Pfeil become directors; charter and bylaws amended.
- Convertible notes and bond hedges amended; conversion rights now based on Globus Medical common stock.
Key facts
Extracted from this filing and checked against the source text.
Executive change
SEC 8-K Item 5.02
confidence 0.95
Michael Farrington departed as senior vice president at NUVASIVE INC.
- Action
- ceased
- Role
- senior vice president
Exact text from the filing
each of Michael Farrington, Nathaniel B. Sisitsky and Dale Wolf ceased to be senior vice presidents of NuVasive
View on SEC.gov
Executive change
SEC 8-K Item 5.02
confidence 0.95
Daniel Scavilla was appointed as director at NUVASIVE INC.
- Action
- appointed
- Role
- director
Exact text from the filing
Daniel Scavilla and Keith Pfeil, each a director of Merger Sub immediately prior to the Effective Time, became a director of NuVasive
View on SEC.gov
Executive change
SEC 8-K Item 5.02
confidence 0.95
Nathaniel B. Sisitsky departed as senior vice president at NUVASIVE INC.
- Action
- ceased
- Role
- senior vice president
Exact text from the filing
each of Michael Farrington, Nathaniel B. Sisitsky and Dale Wolf ceased to be senior vice presidents of NuVasive
View on SEC.gov
Executive change
SEC 8-K Item 5.02
confidence 0.95
Dale Wolf departed as senior vice president at NUVASIVE INC.
- Action
- ceased
- Role
- senior vice president
Exact text from the filing
each of Michael Farrington, Nathaniel B. Sisitsky and Dale Wolf ceased to be senior vice presidents of NuVasive
View on SEC.gov
Executive change
SEC 8-K Item 5.02
confidence 0.95
Keith Pfeil was appointed as director at NUVASIVE INC.
- Action
- appointed
- Role
- director
Exact text from the filing
Daniel Scavilla and Keith Pfeil, each a director of Merger Sub immediately prior to the Effective Time, became a director of NuVasive
View on SEC.gov
M&A Transactions
SEC 8-K Item 2.01/5.01
confidence 0.9
NUVASIVE INC underwent a change of control involving Globus Medical, Inc. for 0.75 fully paid and non-assessable shares of Globus Medical Class A Common Stock per share of NuVasive Common Stock (closed 2023-09-01).
- Action
- change of control
- Counterparty
- Globus Medical, Inc.
- Consideration
- 0.75 fully paid and non-assessable shares of Globus Medical Class A Common Stock per share of NuVasive Common Stock
- Closing
- 2023-09-01
Exact text from the filing
immediately prior to the Effective Time (other than certain excluded shares as described in the Merger Agreement) was cancelled and converted into the right to receive 0.75 fully paid and non-assessable shares (the “Exchange Ratio” and such shares, the “Merger Consideration”) of Globus Medical Class A Common Stock, with cash in lieu of fractional
View on SEC.gov
Material Agreements
SEC 8-K Item 1.01/1.02
confidence 0.9
NUVASIVE INC terminated Second Amended and Restated Credit Agreement with Bank of America, N.A. (effective 2023-09-01).
- Action
- termination
- Agreement
- credit facility
- Counterparty
- Bank of America, N.A.
- Effective
- 2023-09-01
Exact text from the filing
the Company terminated all commitments and repaid in full all obligations due under the Second Amended and Restated Credit Agreement, dated as of February 24, 2020
View on SEC.gov
Material Agreements
SEC 8-K Item 1.01/1.02
confidence 0.9
NUVASIVE INC entered into First Supplemental Indenture with Wilmington Trust, National Association (effective 2023-09-01).
- Action
- entry
- Agreement
- notes offering
- Counterparty
- Wilmington Trust, National Association
- Effective
- 2023-09-01
Exact text from the filing
on the Closing Date, the Company, Globus Medical and Wilmington Trust, National Association (the “Trustee”) entered into that certain First Supplemental Indenture (the “Supplemental Indenture”) to the indenture dated as of March 2, 2020
View on SEC.gov
This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice.
See methodology for how this pipeline works.